BioSpace News Archive

Pharm Country

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 18, 2023

OptiNose, Inc. announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose.

April 18, 2023

·

1 min read

Biotech Bay

Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ixo-vec (ixoberogene soroparvovec), an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP).

April 18, 2023

·

7 min read

Business

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

Aquestive Therapeutics, Inc. today announced that it will report results for first quarter ended March 31, 2023, and provide an update on recent developments in its business after market close on Tuesday, May 2, 2023.

April 18, 2023

·

3 min read

Spectral Medical Announces Positive Results of EUPHAS-2 Clinical Trial Evaluating PMX in Critically Ill Endotoxemic Septic Shock Patients

Spectral Medical Inc. today announced positive results in EUPHAS-2.

April 18, 2023

·

5 min read

Biotech Beach

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Arcutis Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for roflumilast foam 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older.

April 18, 2023

·

7 min read

Biotech Bay

NEUSPERA MEDICAL® ANNOUNCES FDA CLEARANCE OF ITS SYSTEM FOR PERIPHERAL NERVE STIMULATION

Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system.

April 18, 2023

·

2 min read

Genetown

Corbus Pharmaceuticals Hosting Virtual ‘Meet the Expert’ Series: Blocking TGFβ with CRB-601--a New Play for an Old Target

Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced that the Company will host the first in the series of virtual ‘Meet the Expert’ events titled Blocking TGFβ with CRB-601—a New Play for an Old Target, on April 25th at 11:00 AM ET.

April 18, 2023

·

3 min read

Drug Development

OnQuality Pharmaceuticals Presented Preclinical Data for OQL025 and OQL06x, Novel Therapeutics for EGFR inhibitor-induced acneiform rash and diarrhea, at the AACR Annual meeting

OnQuality Pharmaceuticals today announced it presented preclinical data on OQL025 and OQL06x, at the American Association for Cancer Research (AACR) annual meeting. The conference is being held in Orlando, FL, April 14-19, 2023.

April 18, 2023

·

5 min read

Business

Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s

Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).

April 18, 2023

·

3 min read

Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Xenon Pharmaceuticals Inc. today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023.

April 18, 2023

·

1 min read